Taurine

SKU: orb1311013

Description

Taurine

Research Area

Cell Biology, Metabolism Research

Key Properties

• CAS Number: 107-35-7
• MW: 125.15
• Purity: 99.87%
• Formula: C₂H₇NO₃S
• SMILES: NCCS(O)(=O)=O
• Target: Autophagy,LDL,Endogenous Metabolite
• Solubility: DMSO:< 1 mg/mL (insoluble or slightly soluble);H2O:88.3 mg/mL (705.55 mM)

Bioactivity

• Target IC50:
  Hepatocyte cells (rat):24.23 g/L|L6 cells:> 90 μg/mL|HEK293 cells:10 μM (EC50)
• In Vivo:
  METHODS: To investigate the effect on the fibrotic phase of bleomycin-induced lung injury, TD139 (10 µg) was administered as an endotracheal drip to the lungs of mice with pulmonary fibrosis four times every two days. RESULTS: In the lungs of WT mice treated with TD139, there was a significant reduction in fibrosis and β-catenin activation, as well as a decrease in galectin-3 expression.TD139 significantly reduced the total amount of pulmonary collagen. At the same time, the fibrosis score decreased from 3.8±0.4 to 2.6±0.3. In the absence of bleomycin, TD139 had no effect on fibrosis.
• In Vitro:
  METHODS: Primary alveolar epithelial cells from mice were treated with TGF-β1 (1-3 ng/mL) and TD139 (10 µM), and the expression levels of target proteins were detected by Western Blot. RESULTS: TD139 blocked TGF-β1-induced β-catenin phosphorylation. METHODS: FTC-133 and 8505C cells were treated with TD139 (0-100 µM) for 72 h. Cell viability was determined by CCK8 assay. RESULTS: TD139 decreased cell viability in a dose-dependent manner.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Inhibitor, LDL, Endogenous Metabolite, EndogenousMetabolite, antioxidant, antiatherogenic, Autophagy, cardiovascular, bile, blood, 2-Aminoethanesulfonic acid, Taurine, salts, pressure-lowering, VLDL

Compound Identifiers

PubChem CID

1123